Alessio Giubellino

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e56083. 2013
  2. pmc Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892 1109, USA
    Cancer Lett 316:46-52. 2012
  3. pmc Grb2 signaling in cell motility and cancer
    Alessio Giubellino
    National Cancer Institute, Urologic Oncology Branch, CCR, Building 10, 10 Center Drive MSC 1107, Bethesda, MD 20892 1107, USA
    Expert Opin Ther Targets 12:1021-33. 2008
  4. ncbi request reprint Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch, Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1107, USA
    Cancer Res 67:6012-6. 2007
  5. pmc Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch and Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Chem 51:7459-68. 2008
  6. pmc Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Endocrinology 154:646-55. 2013
  7. pmc Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma
    Carole Sourbier
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cell Cycle 9:4183-9. 2010
  8. pmc Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids
    Won Jun Choi
    Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute, National Insitutes of Health, Frederick, Maryland 21702, USA
    J Med Chem 52:1612-8. 2009
  9. pmc Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides
    Fa Liu
    Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Frederick, Frederick, MD 21702, USA
    Biopolymers 96:780-8. 2011
  10. pmc Targeting the Met signaling pathway in renal cancer
    Alessio Giubellino
    Urologic Oncology Branch, CCR, National Cancer Institute, Bethesda, MD 20892 21107, USA
    Expert Rev Anticancer Ther 9:785-93. 2009

Collaborators

Detail Information

Publications18

  1. pmc Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e56083. 2013
    ..Levels of Hsp70 in plasma from the xenograft studies served as a proximal biomarker of drug treatment. Our study suggests that targeting Hsp90 may benefit patients with advanced pheochromocytoma...
  2. pmc Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892 1109, USA
    Cancer Lett 316:46-52. 2012
    ....
  3. pmc Grb2 signaling in cell motility and cancer
    Alessio Giubellino
    National Cancer Institute, Urologic Oncology Branch, CCR, Building 10, 10 Center Drive MSC 1107, Bethesda, MD 20892 1107, USA
    Expert Opin Ther Targets 12:1021-33. 2008
    ..Metastasis is the primary cause of death in most human cancers, and understanding the molecular mechanisms underpinning this multistep process is fundamental to identifying novel molecular targets and developing more effective therapies...
  4. ncbi request reprint Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch, Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1107, USA
    Cancer Res 67:6012-6. 2007
    ..These results support the potential efficacy of this compound in reducing the metastatic spread of primary solid tumors and establish a critical role for Grb2 Src homology-2 domain-mediated interactions in this process...
  5. pmc Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch and Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Chem 51:7459-68. 2008
    ..This approach to defining protein binding antagonist selectivity and molecular basis of action should be widely applicable in drug development...
  6. pmc Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Endocrinology 154:646-55. 2013
    ..This study suggests that targeting both mTORC1 and mTORC2 is a potentially rewarding strategy and supports the application of selective inhibitors in combinatorial drug regimens for metastatic pheochromocytoma...
  7. pmc Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma
    Carole Sourbier
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cell Cycle 9:4183-9. 2010
    ..Increasing tumor ROS with bortezomib in combination with cisplatin represents a novel targeted therapeutic approach to treat advanced HLRCC-associated renal tumors...
  8. pmc Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids
    Won Jun Choi
    Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute, National Insitutes of Health, Frederick, Maryland 21702, USA
    J Med Chem 52:1612-8. 2009
    ..These results could provide a foundation for further structural optimization of Shc SH2 domain-binding peptide mimetics...
  9. pmc Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides
    Fa Liu
    Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Frederick, Frederick, MD 21702, USA
    Biopolymers 96:780-8. 2011
    ..The synthetic approach may be useful in RCM macrocyclizations, where maintenance of proline integrity at both ring junctures is desired...
  10. pmc Targeting the Met signaling pathway in renal cancer
    Alessio Giubellino
    Urologic Oncology Branch, CCR, National Cancer Institute, Bethesda, MD 20892 21107, USA
    Expert Rev Anticancer Ther 9:785-93. 2009
    ..This review will focus on efforts to understand the role of the Met signaling pathway in renal cancer and how this has contributed to the development of potent and selective drug candidates...
  11. doi request reprint NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model
    Karel Pacak
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 131:2445-55. 2012
    ....
  12. pmc High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, United States of America
    PLoS ONE 9:e90458. 2014
    ..Our study exemplifies a promising model to identify potential drugs from a group of clinically approved compounds that can more rapidly be implemented into clinical trials in patients with metastatic pheochromocytoma or paraganglioma. ..
  13. pmc Combination of 13-cis retinoic Acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice
    Svenja Nölting
    Eunice Kennedy Shriver National Institute of Child Health and Human Development S N, A Gi, Y T, P B, J S, K P, National Institutes of Health, Bethesda, Maryland 20892 Department of Endocrinology S N, K Y, M K, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom Department of Internal Medicine II S N, B G, G V, Campus Grosshadern, University Hospital of the Ludwig Maximilians University of Munich, and Institute of Medical Informatics, Biometry, and Epidemiology M L, University of Munich, Munich 81377, Germany Department of Molecular Medicine P B, Institute of Virology, Slovak Academy of Sciences, Bratislava 84505, Slovakia Department of Internal Medicine III J S, Nephrology, Rheumatology, and Endocrinology, Faculty of Medicine and Dentistry, Palacky University, Olomouc 77520, Czech Republic Leidos Biomedical Research, Department of Anesthesia
    Endocrinology 155:2377-90. 2014
    ..Therefore, this drug combination may be a well-tolerated novel therapeutic or preventive option for malignant PCC. ..
  14. ncbi request reprint Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis
    Fa Liu
    Laboratory of Medicinal Chemistry, Bldg 376 Boyles St, Center for Cancer Research, NCI Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Org Biomol Chem 5:367-72. 2007
    ..9 nM). The results of this study advance design considerations that should facilitate the development of Grb2 SH2 domain-binding antagonists...
  15. ncbi request reprint Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy
    Pathirage G Dharmawardana
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1107, USA
    Anticancer Drugs 17:13-20. 2006
    ..These novel compounds offer considerable promise in our growing arsenal of rationally designed anti-cancer therapeutics...
  16. ncbi request reprint c-Met ectodomain shedding rate correlates with malignant potential
    Gagani Athauda
    Urologic Oncology Branch, Laboratory of Molecular Pharmacology, and Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1107, USA
    Clin Cancer Res 12:4154-62. 2006
    ..We hypothesized that c-Met overexpression in cancer might result in increased ectodomain shedding, and that its measure could be a useful biomarker of tumor progression...
  17. pmc Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells
    Angelina Felici
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National, Institutes of Health, Bethesda, Maryland 20892 1501, USA
    J Cell Biochem 111:310-21. 2010
    ..Our results suggest that in myeloid cells, Gab1 is likely to enhance HGF mitogenicity by coupling Met to Shp-2 and GATA-2 expression, thereby potentially contributing to normal myeloid differentiation as well as oncogenic transformation...
  18. pmc Microarray analysis sheds light on the dedifferentiating role of agouti signal protein in murine melanocytes via the Mc1r
    Elodie Le Pape
    Pigment Cell Biology Section, Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:1802-7. 2009
    ....